Zacks Research Issues Negative Estimate for BIO Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Equities researchers at Zacks Research cut their Q1 2026 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a research note issued to investors on Monday, March 2nd. Zacks Research analyst Team now forecasts that the medical research company will post earnings of $2.77 per share for the quarter, down from their previous forecast of $2.79. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2026 earnings at $2.34 EPS, Q4 2026 earnings at $2.59 EPS, FY2026 earnings at $10.32 EPS, Q1 2027 earnings at $2.22 EPS, Q2 2027 earnings at $2.30 EPS, Q3 2027 earnings at $2.35 EPS and FY2027 earnings at $9.30 EPS.

Several other equities research analysts have also recently issued reports on BIO. Wall Street Zen cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Bio-Rad Laboratories has a consensus rating of “Hold” and an average target price of $358.50.

Bio-Rad Laboratories Stock Up 1.7%

Shares of NYSE BIO opened at $284.83 on Tuesday. The company has a market capitalization of $7.69 billion, a P/E ratio of 10.21 and a beta of 1.18. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.62 and a quick ratio of 4.19. The company has a 50 day simple moving average of $296.91 and a 200-day simple moving average of $301.34. Bio-Rad Laboratories has a 1 year low of $211.43 and a 1 year high of $343.12.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, February 12th. The medical research company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.06). Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.The firm had revenue of $693.20 million for the quarter, compared to analysts’ expectations of $694.64 million. During the same period last year, the firm earned $2.90 earnings per share. Bio-Rad Laboratories’s revenue for the quarter was up 3.9% on a year-over-year basis.

Institutional Trading of Bio-Rad Laboratories

Large investors have recently modified their holdings of the stock. Rehmann Capital Advisory Group purchased a new position in Bio-Rad Laboratories in the fourth quarter valued at $201,000. Virtu Financial LLC acquired a new stake in Bio-Rad Laboratories in the 4th quarter valued at about $672,000. Corient Private Wealth LLC boosted its stake in shares of Bio-Rad Laboratories by 4,570.8% in the 4th quarter. Corient Private Wealth LLC now owns 66,792 shares of the medical research company’s stock valued at $20,237,000 after buying an additional 65,362 shares during the period. Vident Advisory LLC acquired a new position in shares of Bio-Rad Laboratories during the fourth quarter worth about $892,000. Finally, State of Tennessee Department of Treasury increased its stake in shares of Bio-Rad Laboratories by 35.1% during the fourth quarter. State of Tennessee Department of Treasury now owns 3,796 shares of the medical research company’s stock worth $1,115,000 after buying an additional 987 shares during the period. Hedge funds and other institutional investors own 65.24% of the company’s stock.

More Bio-Rad Laboratories News

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Zacks raised its Q1 2027 EPS forecast to $2.22 (from $2.12), a modest upward revision that could be read as a small near-term beat to expectations for that quarter.
• Neutral Sentiment: Zacks published an initial FY2028 EPS estimate of $9.87. As an early/forward-year projection this is informative but carries uncertainty and is not directly comparable to current-year consensus figures.
• Negative Sentiment: Zacks cut a string of near‑ and medium‑term EPS forecasts — small trims to Q1 2026 ($2.77), Q2 2026 ($2.34), Q4 2026 ($2.59) and FY2026 (to $10.32 from $10.36), and larger cuts to FY2027 (to $9.30 from $9.38) and several Q2–Q3 2027 quarters — signaling a weaker earnings trajectory than previously modeled. These downward revisions, taken together, are the main negative catalyst from this batch of research notes because they lower forward earnings expectations and could pressure valuation multiples.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.